LIXT 8-K SEC Filing Analysis

Latest settled — T+5d

LIXT ▼ -2.91% at T+5d

LONG call ✗ call lost -2.91% · α vs SPY -0.16% · entry $7.21 → $7.00

Next anchor: T+20d in 17d

Currently $6.19 · -14.15% from $7.21 entry

Entry anchored
Jun 1, 08:55 AM ET
via Databento tick

T+1d

-2.36%

call -2.36% · α -2.50%

$7.04

settled 11d ago

T+5d

-2.91%

call -2.91% · α -0.16%

$7.00

settled 5d ago

T+20d

—

call — · α —

—

in 17d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

LIXTE Biotechnology announced a strategic transformation into an AI energy infrastructure equipment & services platform, seeking a buyer for its clinical-stage pharma and med-tech operations. Stuart D. Porter, founder of Denham Capital with over $12B in energy investments, joined the board, signaling credibility for the new direction.

Actionable Insight

The transformation could re-rate LIXT as an AI infrastructure play. Watch for acquisition updates, capital raises, and details on the pharma divestiture. The addition of Porter suggests institutional credibility, but execution risk remains high.

Key Facts

Company pivoting from clinical-stage biotech to AI energy infrastructure equipment & services
Stuart D. Porter (Denham Capital founder) appointed to board, bringing 29+ years energy investment experience
Denham Capital's infrastructure group progressing ~10 GW pipeline of AI data-center power generation opportunities
Company seeks strategic acquisition partner for its pharmaceutical and med-tech operations
No financial terms or guidance provided in the filing

Financial Impact

No specific financial figures disclosed; strategic pivot targets large AI data-center power market (NERC projects 224 GW peak demand increase)

Risk Factors

Execution risk in pivoting from biotech to energy infrastructure with no prior experience
Potential dilution from future capital raises to fund acquisitions
No revenue or earnings from the new business yet
Uncertainty around valuation and timing of pharma asset sale

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-026544
Exhibit: ex99-1.htm	0001493152-26-026544
Document: 0001493152-26-026544-index-headers.html	0001493152-26-026544
Document: 0001493152-26-026544-index.html	0001493152-26-026544
Document: 0001493152-26-026544.txt	0001493152-26-026544

7 reports for LIXT

T+1T+5T+20T+60

Filters

Reports for LIXT — sortable, filterable
	Type				Now
Jun 12, 2026 today	Press Release BULLISH ★ 7/10	$7.20 awaiting T+5	awaiting T+5	—	$6.19 (−13.97%)
Jun 4, 2026 8d ago	8-K BEARISH ★ 6/10	$6.83 awaiting T+5	awaiting T+5	—	$6.19 (+9.37%)
Jun 4, 2026 8d ago	424B5 BEARISH ★ 6/10	$7.06 awaiting T+5	awaiting T+5	—	$6.19 (+12.32%)
Jun 1, 2026 11d ago	8-K BULLISH ★ 6/10	$7.21 $7.00	▼ −2.91%	▼ −0.16%	$6.19 (−14.15%)
May 14, 2026 29d ago	Press Release NEUTRAL ★ 3/10	$5.16 $5.88	▲ +13.95%	▲ +12.99%	$6.19 (+19.96%)
Apr 17, 2026 8w ago	8-K NEUTRAL ★ 3/10	$3.44 $3.80	▲ +10.47%	▲ +9.55%	$6.19 (+79.94%)
Apr 13, 2026 8w ago	Press Release NEUTRAL ★ 5/10	$2.93 $3.44	▲ +17.41%	▲ +14.11%	$6.19 (+111.26%)

US Market Status

Market Closed — Opens Mon (53h 8m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access